Profile: GenVec Inc (GNVC.OQ)
20 Dec 2013
GenVec, Inc. (GenVec), incorporated in 1992, is a biopharmaceutical company using differentiated, technologies to create superior therapeutics and vaccines. A key component of its strategy is to develop and commercialize its product candidates through collaborations. GenVec is working with companies and organizations, such as Novartis, Merial, and the United States Government to support a portfolio of product programs that address the prevention and treatment of a number of human and animal health concerns. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company’s products are developed with its adenovector technology, which uses modified adenoviruses to deliver genes to target cells.
As of December 31, 2011, in partnership with the Company’s collaborators it had multiple vaccines in development. These programs are funded by third-parties and utilize its core adenovector technology. GenVec has grant-supported preclinical programs to develop vaccine candidates for the prevention of RSV and HSV. In addition, it has collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to develop a HIV vaccine and an influenza virus vaccine. It also has programs with the United States Naval Medical Research Center (NMRC) to develop vaccines for dengue fever and malaria. In addition, it has provided vaccine candidates to the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) against HIV. In the field of animal health, it is working with Merial to commercialize vaccines for the prevention of a major animal health problem, FMD. Development efforts for this program are also supported by the United States Department of Homeland Security (DHS) and in collaboration with the United States Department of Agriculture (USDA) as of December 31, 2011.
Therapeutic Product Development Programs
In collaboration with Novartis, the Company’s hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. Hearing and balance require specialized cells of the inner ear called sensory hair cells. Embryonic development is an atonal gene (Atoh1) induces the generation of these cells.
Vaccine Development Programs
In addition to the Company’s therapeutic product development programs, the Company is working with collaborators to develop vaccines using its adenovector technology. As of December 31, 2011, it was developing preventative vaccines, including RSV, HSV, dengue fever, and malaria.
The Company competes with Sanofi-Aventis, Novartis, GlaxoSmithKline, MedImmune, Inc., AstraZeneca, Merck, Pfizer, Crucell, Bavarian Nordic, Okairos, Intercell, Genocea, Vical, Emergent Biosolutions, Novavax, Quark Pharmaceuticals, Sound Pharmaceuticals, Auris Medical, Genocea, Vical, Alphavax, Juvaris, VaxGen, Sanofi, Crucell, Genocea, Sanaria and Okairos Merial, Intervet, Bayer and Indian Immunologicals.
65 West Watkins Mill Road
GAITHERSBURG MD 20878